Biotech developing furmonertinib, an EGFR-targeted lung-cancer drug in-licensed from a Chinese partner, for global markets.
Biotech developing furmonertinib, an EGFR-targeted lung-cancer drug in-licensed from a Chinese partner, for global markets.
Pre-revenue: it sells nothing and pays for trials from cash raised in its early-2024 listing and other share sales. Rights to furmonertinib outside Greater China come from Shanghai Allist, which sells it in China, so any US approval would bring milestone and royalty payments to Allist.
Moat: narrow (IP / patents). Exclusive ex-China rights to a differentiated EGFR inhibitor already approved in China.
Headquarters: Newtown Square, Pennsylvania, US · Founded: 2021 · Employees: 77
Size ArriVent BioPharma (AVBP) is a United States Health Care company (Pharmaceuticals: Other) with a market value of $564M, the 2583rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.90 on 18 Nov 2026.
Performance Over six months the shares fell 60.0%, against -22.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth The operating margin is -3,620.0% (peer median 12.2%).
Valuation It trades at 34.2× enterprise value to sales against a peer median of 2.9× (most expensive of 20).
Short interest Short interest is 11.8% of the free float (30 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $5.00M | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | n/a | $0 | $0 | $0 | $0 |
| EBITDA | -$181M | -$178M | -$94.3M | -$74.6M | -$36.9M |
| Net income | -$169M | -$166M | -$80.5M | -$69.3M | -$36.9M |
| Free cash flow | -$153M | -$161M | -$70.2M | -$55.8M | -$43.6M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $256,000 | $14,000 | $176,000 | $317,000 | $139,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| ArriVent BioPharma AVBP | $564M | -60% | n/a | -3,620% | 34.2× | n/a |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVBP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -42.2% | -10.3% | lowest of 21 |
| 6-month return | -60.0% | -22.1% | lowest of 21 |
| Distance from 52-week high | -69.6% | -44.4% | lowest of 21 |
| Operating margin | -3,620.0% | 12.2% | lowest of 21 |
| EV / Sales | 34.2× | 2.9× | most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ArriVent BioPharma AVBP | United States | $564M | -60% | n/a | -3,620% | 34.2× | n/a | n/a |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $548M | -9% | +6% | 6% | 3.3× | 15.4% | +6.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 3.8× | 19.1% | +12.1% |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 4.9× | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $532M | -2% | -4% | 21% | 3.0× | 1.4% | +7.0% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | 2.0× | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | 1.8× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | 1.5× | 4.0% | +13.5% |
| Lionco Pharmaceutical 603669.SS | China | $474M | +4% | -6% | -17% | 8.4× | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $466M | -20% | +7% | 35% | 0.7× | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | 3.4× | 0.4% | +4.8% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | 2.2× | 2.1% | -1.3% |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 1.5× | 14.1% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | n/a | n/a | n/a |
| Tibet Aim Pharm 002826.SZ | China | $407M | -22% | +13% | 14% | 2.9× | 0.4% | +1.0% |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 4.6× | 24.3% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 2.1× | n/a | n/a |
| Boiron BOI.PA | France | $367M | -31% | -2% | 5% | 0.6× | -0.8% | -0.5% |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 5.6× | 4.7% | +18.5% |
| Daiken Biomedical 7780.TW | Taiwan | $342M | -19% | n/a | 18% | 3.0× | -1.6% | n/a |
| Grape King Bio 1707.TW | Taiwan | $342M | -27% | -5% | 19% | 1.0× | -17.2% | +2.3% |